ClinicalTrials.gg
CompletedNCT06843343DEVILSUpdated Nov 17, 2026Results posted

Dispersion Following ESP Versus ITP Blocks Using Lidocaine Study

A Phase 4 interventional study of Intertransverse Process Block with 1.5% Lidocaine and Erector Spinae Plane Block with 1.5% Lidocaine in Acute Pain, Postoperative and Regional Anesthesia Block, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Duke University · Phase 4, Interventional, and Other

How we know

Updated Nov 17, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Pain, Postoperative by Duke University — 6 open to participants now, 6 under way, none of them phase 3. Pain, Postoperative · Duke University.

Enrollment
15th of 17
13 · median 53
Started
2025
with 1 other
Phase 4
11 of 19
5 open now
Registered
14th of 19
by date

Among the 19 studies in Pain, Postoperative by Duke University, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 in phase 4, and was the 14th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

6 of the 19 studies in Pain, Postoperative by Duke University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pain, Postoperative by Duke University, or all of them as a file.
02

Study summary

Regional anesthesia techniques (or nerve blocks) are used to provide sensory blockade over the chest wall. The most established technique is thoracic epidural. This provides bilateral spread but is also associated with neuraxial complications, which has led to a decrease in clinical usage. Alternative peripheral nerve block techniques, such as intercostal nerve blocks, eliminate the neuraxial complications but, in turn, require numerous injections to provide unilateral coverage. The introduction of ultrasound-guided (USG) nerve blocks has generated clinical interest in the development of novel paraspinal (non-epidural) nerve block techniques, which will provide multiple dermatomal coverage with a single injection. Two such techniques are the Erector Spinae Plane (ESP) block and the Intertransverse Process (ITP) block. The Intertransverse Process (ITP) block targets a slightly deeper plane than the Erector Spinae Plane (ESP) block and was specifically designed to address the ESP block's variable anesthetic spread. Despite its potential for more localized and precise dermatomal coverage, no prior studies have directly compared the two techniques in terms of their cutaneous distribution.

Read the detailed description

To compare the dermatomal sensory block distribution, the investigators will use detailed mapping with pinprick, cold, and heat stimuli. The investigators expect similar systemic absorption, the chances of local anesthetic systemic toxicity (LAST) should be equally low, and both blocks should be similarly safe. A total of 14-18 healthy adult volunteers will be included. There will be two different procedure days, separated by at least one week. On each day, the subjects will receive a paraspinal block. Each volunteer will undergo pre-procedure screening on the first visit. The blocks will be performed on the same side, at the same level, by the same anesthesiologist, at least one week apart. An ultrasound-guided ESP block will be administered in one day, and an ITP block on the other. Sensory testing will be performed at baseline and 60-90 minutes after the block injections. Serial samples of blood will be drawn to analyze lidocaine PK (between 0 and 240 minutes post-block).

03

Conditions studied

  • Acute Pain, Postoperative
  • Regional Anesthesia Block

Browse trials for

Keywords

  • Erector Spinae Plane Block
  • ESP Block
  • ESP
  • Intertransverse Block
  • ITP Block
  • ITP
  • Regional Anesthesia
  • Paraspinal Blocks
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written
  • Ability and willingness to comply with the study procedures and duration requirements
  • 1 or 2
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • > 35kg.m2
  • Use of analgesics within 24 hours before the procedure
  • History of thoracic trauma or surgery
  • Thoracic deformities or abnormalities that may prevent proper block performance
  • Thoracic tattoos
  • Systemic neuromuscular disease
  • to regional anesthesia (e.g., infection, allergy, challenging sonoanatomy)
  • Other known health conditions that would affect the participant's ability to successfully complete the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    Erector Spinae Plane (ESP) Block

    Participants receive ESP Block under ultrasound guidance, with 20mL of 1.5% Lidocaine on one visit.

    Procedure: Erector Spinae Plane Block with 1.5% Lidocaine · Drug: 1.5% Lidocaine

  • Experimental
    Intertransverse Process Block (ITP) Block

    Participants receive ITP Block under ultrasound guidance, with 20mL of 1.5% Lidocaine on the other visit.

    Procedure: Intertransverse Process Block with 1.5% Lidocaine · Drug: 1.5% Lidocaine

Interventions

  • ProcedureIntertransverse Process Block with 1.5% Lidocaine

    For the ITP block, the needle will be advanced further into the intertransverse tissue complex between the T4 and T5 transverse processes, and local anesthetic will be injected just above the superior costotransverse ligament, under ultrasound guidance.

  • ProcedureErector Spinae Plane Block with 1.5% Lidocaine

    The ESP block will be performed by advancing the needle to the transverse process, under ultrasound guidance, with local anesthetic injected between the erector spinae muscle and the transverse process, targeting a caudad-cephalad spread.

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    local anesthetic to be used in either the ITP and ESP block

06

What researchers measure

Primary outcomes

  1. Temperature Discrimination

    Skin temperature assessment using gloved ice on the chest wall, to discriminate blocked vs unblocked. Reported as the blocked area in cm\^2.

    Time frame: 60 to 90 minutes post each intervention (interventions occurred 7 days apart)

  2. Mechanical Discrimination

    Mechanical assessment using a neuropin (pinprick) on the chest wall, to discriminate blocked vs unblocked. Reported as the blocked area in cm\^2.

    Time frame: 60 to 90 minutes post each intervention (interventions occurred 7 days apart)

Secondary outcomes

  1. Thermography

    Infrared camera will assess skin temperature of the chest wall.

    Time frame: 60 to 90 minutes post each intervention (interventions occurred 7 days apart)

  2. Nociceptive Discrimination

    Nociceptive stimuli will be delivered using controlled heat to discriminate blocked versus unblocked areas on the chest wall.

    Time frame: 60 to 90 minutes post each intervention (interventions occurred 7 days apart)

Other outcomes

  1. Number of Participants With Adverse Events

    Time frame: 2 days post each block, up to 9 days

07

Results

Posted Nov 17, 2026

Participant flow

13 subjects were recruited to receive both blocks.

First Intervention (1 Day)
Participant flow — First Intervention (1 Day)
MilestoneErector Spinae Plane Block, Then Intertransverse Process BlockIntertransverse Process Block, Then Erector Spinae Plane Block
Started76
Completed76
Not completed00
Second Intervention (1 Day)
Participant flow — Second Intervention (1 Day)
MilestoneErector Spinae Plane Block, Then Intertransverse Process BlockIntertransverse Process Block, Then Erector Spinae Plane Block
Started76
Completed76
Not completed00

Outcome measures

PrimaryTemperature Discrimination

Skin temperature assessment using gloved ice on the chest wall, to discriminate blocked vs unblocked. Reported as the blocked area in cm\^2.

Time frame:
60 to 90 minutes post each intervention (interventions occurred 7 days apart)
Reported as:
Median · cm^2
Temperature Discrimination
cm^2Erector Spinae Plane (ESP) BlockIntertransverse Process Block (ITP) Block
temperature anterior0 (0 to 4.7)2.96 (0 to 8.29)
temperature posterior28.3 (14.21 to 82.28)41.56 (34 to 52.9)
temperature lateral10.24 (2.32 to 13.64)18.16 (8.25 to 30.88)
PrimaryMechanical Discrimination

Mechanical assessment using a neuropin (pinprick) on the chest wall, to discriminate blocked vs unblocked. Reported as the blocked area in cm\^2.

Time frame:
60 to 90 minutes post each intervention (interventions occurred 7 days apart)
Reported as:
Median · cm^2
Mechanical Discrimination
cm^2Erector Spinae Plane (ESP) BlockIntertransverse Process Block (ITP) Block
mechanical anterior0 (0 to 7.46)2.65 (0 to 9.54)
mechanical posterior20.35 (7.9 to 24.89)32.14 (21.88 to 42.69)
mechanical lateral2.83 (1.29 to 17.76)17.83 (9.03 to 28.34)
SecondaryThermography

Infrared camera will assess skin temperature of the chest wall.

Time frame:
60 to 90 minutes post each intervention (interventions occurred 7 days apart)
Reported as:
Median · degrees Celsius
Thermography
degrees CelsiusErector Spinae Plane (ESP) BlockIntertransverse Process Block (ITP) Block
Anterior temperature33.5 (32.5 to 34.2)33.4 (33 to 34.1)
Posterior temperature33.9 (33.1 to 34.2)34.05 (33.55 to 34.32)
Lateral temperature34.6 (33.5 to 35.2)34.35 (34.2 to 34.97)
SecondaryNociceptive Discrimination

Nociceptive stimuli will be delivered using controlled heat to discriminate blocked versus unblocked areas on the chest wall.

Time frame:
60 to 90 minutes post each intervention (interventions occurred 7 days apart)
Reported as:
Mean · degrees Celsius
Nociceptive Discrimination
degrees CelsiusErector Spinae Plane (ESP) BlockIntertransverse Process Block (ITP) Block
Temperature anterior45.73 ± 2.6447.95 ± 1.51
Temperature posterior47.89 ± 1.7949.17 ± 1.47
Temperature lateral46.05 ± 2.3147.36 ± 1.89
Other pre-specifiedNumber of Participants With Adverse Events
Time frame:
2 days post each block, up to 9 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsErector Spinae Plane (ESP) BlockIntertransverse Process Block (ITP) Block
Number of Participants With Adverse Events00

Adverse events

Collected over 2 days post each block, up to 9 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Erector Spinae Plane Block0/13 (0%)0/13 (0%)0/13 (0%)
Intertransverse Process Block0/13 (0%)0/13 (0%)0/13 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Participants
Mean31.77 ± 9.51
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female3
Male10
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)All Study Participants
Height
Height(cm)All Study Participants
Mean175.12 ± 12.34
Weight
Weight(kg)All Study Participants
Mean83.77 ± 27.04
BMI
BMI(kg/m^2)All Study Participants
Mean27.04 ± 3.14
08

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27701, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jul 2025, 1 month.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 1 month is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 24, 2025
StartActual
Jun 10, 2025
Primary completionActual
Jul 26, 2025
CompletionActual
Aug 1, 2025
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedTemperature discriminationDiscriminationTime frame: 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
  • EditedMechanical discriminationDiscriminationTime frame: 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
  • RemovedCutaneous distribution mappingTime frame: 60 to 90 minutes post-block
Nov 17, 2026
Documents
Secondary outcomes
2 edited, 1 time frame changed, 2 removed
What changed in the outcomes
  • EditedNociceptive discriminationDiscriminationTime frame: Baseline and 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
  • RemovedPulmonary Function TestTime frame: Baseline and 60 to 90 minutes post-block
  • RemovedLidocaine pharmacokineticsTime frame: Basiline, 10, 20, 30, 45, 60, 90, 120 and 240 minutes post block.
  • Time frameThermographyBaseline and 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
  • Editedother outcomeNumber of Participants With Adverse EventsTime frame: End of study (2 days post blocks). → 2 days post each block, up to 9 days
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Primary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedTemperature discriminationDiscriminationTime frame: 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
    • EditedMechanical discriminationDiscriminationTime frame: 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
    • RemovedCutaneous distribution mappingTime frame: 60 to 90 minutes post-block
    Secondary outcomes 2 edited, 1 time frame changed, 2 removed
    What changed in the outcomes
    • EditedNociceptive discriminationDiscriminationTime frame: Baseline and 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
    • RemovedPulmonary Function TestTime frame: Baseline and 60 to 90 minutes post-block
    • RemovedLidocaine pharmacokineticsTime frame: Basiline, 10, 20, 30, 45, 60, 90, 120 and 240 minutes post block.
    • Time frameThermographyBaseline and 60 to 90 minutes post-block → 60 to 90 minutes post each intervention (interventions occurred 7 days apart)
    • Editedother outcomeNumber of Participants With Adverse EventsTime frame: End of study (2 days post blocks). → 2 days post each block, up to 9 days
    + 4 other changes: index terms, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06843343
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Jun 10, 2025
Primary completion
Jul 26, 2025
Completion
Aug 1, 2025
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Brian Mendelson, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion